should verify the contents of the documents against a final, official 360c(i), “defining substantial equivalence”). Per section 513(f)(2)(B)(i) of the FD&C Act, the classification is the initial classification of the device for the purposes of section 513(f)(1) of the FD&C Act. rendition of the daily Federal Register on FederalRegister.gov does not This document has been published in the Federal Register. documents in the last year, 789 For more information on how we use cookies, please see our Privacy Policy. Posted by the Food and Drug Administration on … regulatory information on FederalRegister.gov with the objective of to the courts under 44 U.S.C. The OFR/GPO partnership is committed to presenting accurate and reliable The guidance is meant to provide clarity on the Agency’s expectations for information to be submitted in a De Novo request and to ensure predictability and consistency for sponsors. documents in the last year, by the International Trade Administration informational resource until the Administrative Committee of the Federal Upon receipt of a De Novo request, the FDA will conduct an acceptance review. offers a preview of documents scheduled to appear in the next day's So far in 2019, CDRH has granted 15 de novo requests, which compares with 44 requests … This prototype edition of the documents in the last year, 993 by the Financial Crimes Enforcement Network Acceptance review therefore takes on additional importance in both encouraging quality applications from De Novo requesters and allowing the Agency to appropriately concentrate resources on complete applications. FDA-2017-1)-6069: Acceptance Review for De Novo Classification Requests, Draft Guidance for Industry and Food and Drug Administration Staff Dear Sir or Madame: The Advanced Medical Technology Association ("AdvaMed") appreciates the opportunity to provide Please do not post any information that you consider to be personal or confidential. By accepting cookies, you agree to our use of cookies. Instead, other device sponsors can use the 510(k) process, when applicable, as a pathway to market their device. These tools are designed to help you understand the official document Focusing the Agency's review resources on complete De Novo requests will provide a more efficient approach to ensuring that safe and effective medical devices reach patients as quickly as possible. The classification will be according to the criteria under section 513(a)(1) of the FD&C Act. On September 9, 2019, FDA issued guidance for industry and FDA staff explaining FDA’s acceptance review process for De Novo classification requests. for better understanding how a document is structured but documents in the last year, 10 Acceptance Checklist for De Novo Classification Requests) to ensure that the De Novo request is administratively complete to permit a substantive review. We’ve made big changes to make the eCFR easier to use. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled “Acceptance Review for De Novo Classification Requests.” The purpose of this guidance is to explain the procedures and criteria FDA intends to use in assessing whether a request for an evaluation of automatic class III designation (De Novo classification request or De Novo request) meets a minimum threshold of acceptability and should be accepted for substantive review. © documents in the last year, 73 documents in the last year, 29 One of our lawyers will be happy to discuss the possibility of representation with you. establishing the XML-based Federal Register as an ACFR-sanctioned daily Federal Register on FederalRegister.gov will remain an unofficial 1 New Section 513(f)(2) –Evaluation of Automatic Class III Designation, Guidance for Industry and Staff (February 19, 1998). on It does not establish any rights for any person and is not binding on FDA or the public. electronic version on GPO’s govinfo.gov. FDA is issuing this guidance to provide clarity regarding the Agency's expectations for information to be submitted in a De Novo request and ensure predictability and consistency for sponsors. The documents posted on this site are XML renditions of published Federal 7301, Silver Spring, MD 20993-0002, 240-402-7911. To assess whether a De Novo request contains the information necessary for a substantive review, FDA has established an “Acceptance Checklist.” The Checklist, which is provided as Appendix A to the Guidance, includes several preliminary questions, e.g., whether the product is a device or a combination product with a device constituent part, followed by checklists for assessing the completeness of the De Novo request. DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Document page views are updated periodically throughout the day and are cumulative counts for this document. 66, Rm. reclassification are no longer required to submit a De Novo request within 30 days. on [FR Doc. This table of contents is a navigational tool, processed from the documents in the last year, 43 AdvaMed Comments on Docket No. on FederalRegister.gov September 30, 2019. Other. Pre-Submission (Pre-Sub)- Although the Pre-Sub is not required to obtain FDA review of a De Novo request, but it is a useful way to obtain early feedback from the agency on whether a device is eligible for the De Novo classification process, and get advise on the documentation needed for a subsequent De Novo request. If you want to submit a comment with confidential information that you do not wish to be made available to the, For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”, Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. An acceptance review of this information will be conducted within 15 calendar days of receipt of the de novo classification request, user fee payment and a validated e-copy. IP FDA Blog. You should submit two copies total. documents in the last year, by the Energy Department On September 9, 2019, the Food and Drug Administration released a final guidance document, Acceptance Review for De Novo Classification … For complete information about, and access to, our official publications 1061, Rockville, MD 20852. 3501-3520). Re: Docket No. Submit written requests for a single hard copy of the draft guidance document entitled “Acceptance Review for De Novo Classification Requests” to the Office of the Center Director, Guidance and Policy Development, Center for Devices and Radiological Health (CDRH), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. New Documents You can use an alternative approach if it satisfies … 66, Rm. 1538, Silver Spring, MD 20993-0002, 301-796-6419; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. Therefore, if all criteria necessary to meet a minimum threshold of acceptability for De Novo requests as Start Printed Page 47312outlined in this guidance are not included in a De Novo request received by FDA before or up to 60 days after the publication of this guidance, FDA staff does not generally intend to refuse to accept. On October 30, CDRH issued the Final Guidance “De Novo Classification Process (Evaluation of Automatic Class III Designation)” (the “De Novo Guidance”). documents in the last year. Submit written requests for a single hard copy of the guidance document entitled “Acceptance Review for De Novo Classification Requests” to the Office of the Center Director, Guidance and Policy Development, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. The President of the United States communicates information on holidays, commemorations, special observances, trade, and policy through Proclamations. The collections of information in the following FDA regulations, guidance, and forms have been approved by OMB as listed in the following table: Principal Associate Commissioner for Policy. documents in the last year, 648 An acceptance review of this information will be conducted within 15 calendar days of receipt of the de novo classification request, user fee payment and a validated e-copy. In this Issue, Documents 66, Rm. documents in the last year, by the Environmental Protection Agency are not part of the published document itself. better and aid in comparing the online edition to the print edition. documents in the last year, 67 legal research should verify their results against an official edition of During substantive review, the FDA first conducts a classification review to see if an existing legally marketed device of the same type exists. The guidance represents the current thinking of FDA on “Acceptance Review for De Novo Classification Requests.” It does not establish any rights for any person and is not binding on FDA or the public. The purpose of the acceptance review is to assess whether a De Novo request is administratively complete and includes all the information necessary for FDA to conduct a substantive review. inclusion in a De Novo request. 5431, Silver Spring, MD 20993-0002; or the Office of Communication, Outreach, and Development, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. The Public Inspection page Requests for combination products containing an approved drug as a constituent part should include, for each relevant patent, certification that (i) such patent information has not been filed, (ii) the patent has expired, (iii) the date on which the patent will expire, or (iv) the patent is invalid or will not be infringed (i.e., a paragraph iv certification). on NARA's archives.gov. On 9 September 2019 the U.S. Food and Drug Administration (FDA or the agency) issued its final guidance document entitled "Acceptance Review for … The President of the United States manages the operations of the Executive branch of Government through Executive orders. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page! This repetition of headings to form internal navigation links Register documents. On December 13, 2016, the 21st Century Cures Act removed a requirement that a De Novo request be submitted within 30 days of receiving an NSE determination. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on. Although the acceptance review process does not evaluate the quality of a De Novo request, it is structured to facilitate substantive review by ensuring that the De Novo request is administratively complete. Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. The review policies and procedures will allow FDA to review “complete De Novo requests” in order to increase efficiently and meet MDUFA IV performance goals. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 1503 & 1507. About the Federal Register If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. 2019-19350 Filed 9-6-19; 8:45 am], updated on 4:15 PM on Wednesday, December 23, 2020, updated on 8:45 AM on Wednesday, December 23, 2020. As part of the Food and Drug Administration Modernization Act of 1997, the de novo classification pathway functions as an Submit written requests for a single hard copy of the draft guidance document entitled ``Acceptance Review for De Novo Classification Requests'' to the Office of the Center Director, Guidance and Policy Development, Center for Devices and Radiological Health (CDRH), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. the Federal Register. The guidance replaces the 30 October 2017 draft guidance of the same name and describes the administrative steps FDA will take to either Refuse to Accept (RTA) or file a request for an evaluation of automatic class III designation (De Novo request). Applicants should be electronically notified of the status of their request within the 15-day period, after which, accepted applications will undergo the substantive review process. Sergio de del Castillo, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. edition of the Federal Register. Additional disclaimer information. 12/23/2020, 202 However, if the De Novo request is designated RTA, the FDA review clock start date will be the document center’s receipt date of the De Novo request including the additional information that results in an acceptance designation, "even if FDA later requests information that should have been requested during acceptance review." We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We use cookies on this website to provide you with the best user experience. publication in the future. 66, Rm. Contact us for additional information. Alternatively, any person who determines that … documents in the last year, 1491 This guidance refers to previously approved collections of information. A search capability for all Center for Devices and Radiological Health guidance documents is available at https://www.fda.gov/​MedicalDevices/​DeviceRegulationandGuidance/​GuidanceDocuments/​default.htm. 360e)) in order to market a substantially equivalent device (see 21 U.S.C. While every effort has been made to ensure that FDA anticipates that the Agency and industry may need a period of time to operationalize the policies within this guidance. FDA-2017-D-6069: Acceptance Review for De Novo Classification Requests, Draft Guidance for Industry and Food and Drug Administration Staff A De Novo request may be submitted with or without a preceding 510(k). Further, if neither an acceptance or RTA are received within 15 days, the application automatically gets moved to a substantive review. They may identify deficiencies to resolve, in which the requester has 180 days to submit additional information. Register, and does not replace the official print version or the official Only official editions of the FDA considered comments received on the draft guidance that appeared in the Federal Register of October 30, 2017 (82 FR 50144). The President of the United States issues other types of documents, including but not limited to; memoranda, notices, determinations, letters, messages, and orders. The guidance represents the current thinking of FDA on “Acceptance Review for De Novo Classification Requests.” It does not establish any rights for any person and is not binding on FDA or the public. Included within the draft guidance is the Acceptance Checklist for De Novo Classification requests. De Novo Summary (K130218) Page 1 DE NOVO CLASSIFICATION REQUEST FOR XSTAT REGULATORY INFORMATION FDA identifies this generic type of device as: Non-absorbable, expandable, hemostatic sponge for temporary internal use: A non- absorbable, expandable, hemostatic sponge for temporary internal use is a prescription Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Please do not post any information that you consider to be personal or confidential. 12/23/2020, 41 This feature is not available for this document. On September 9, 2019, FDA issued a final guidance, Acceptance Review for De Novo Classification Requests. Register (ACFR) issues a regulation granting it official legal status. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance. These markup elements allow the user to see how the document follows the A draft guidance laid out the procedures and criteria FDA intends to use in assessing whether a De Novo classification request should be accepted for substantive review. USA: Acceptance review policies for de novo classification requests drafted in the form of guidance. Federal Register issue. FDA will not consider a criterion in the Checklist to be “present” if the request fails to include either the requested information or a rationale for the omission or deviation. The Public Inspection page may also Once the acceptance review process is complete, the request will receive an “accept” or “refuse to accept” designation. Information about this document as published in the Federal Register. developer tools pages. on the material on FederalRegister.gov is accurately displayed, consistent with 71, Rm. The automatic class III designation for devices of a new type occurs by operation of law and without any action by FDA, regardless of the level of risk posed by the device. documents in the last year, 236 include documents scheduled for later issues, at the request Draft Guidance for Industry on Acceptance Review for De Novo Classification Requests. Document Drafting Handbook The guidance represents the current thinking of FDA on ``Acceptance Review for De Novo Classification Requests.'' documents in the last year, 1452 documents in the last year, 23 combination product. Federal Register provide legal notice to the public and judicial notice This site displays a prototype of a “Web 2.0” version of the daily Medical device regulators at the US Food and Drug Administration have proposed a more formalized and clarifying approach to registration requirements for devices qualifying for De Novo classification. Persons interested in obtaining a copy of the guidance may do so by downloading an electronic copy from the internet. A Pre-sub is not required in order to obtain FDA review of a De Novo request, but it is useful to obtain early feedback from FDA on whether a device may be eligible for the De Novo classification process, and/or advice on the documentation needed in a subsequent De Novo request. Send one self-addressed adhesive label to assist that office in processing your request. 360c(f)(1)). Any device that is of a new type that was not in commercial distribution before May 28, 1976, is automatically classified as, and remains within, class III and requires premarket approval unless and until FDA takes an action to classify or reclassify the device under section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. These can be useful This is a final version of the 2014 draft by the same name (see our earlier blog post here).On the same day, CDRH also issued the draft guidance “Acceptance Review for De Novo Classification Requests” (the “De Novo RTA Guidance”). Notification of a “refuse to accept” designation should be accompanied by a completed Acceptance Checklist indicating the missing elements that prompted the designation. This PDF is Devices using the de novo classification process are those for which there is no predicate device to rely on, and devices granted a de novo request can serve as a predicate device for a later 510 (k) submission. Persons unable to download an electronic copy of “Acceptance Review for De Novo Classification Requests” may send an email request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of the document. FDA may classify a device through the De Novo classification process, which is the pathway authorized under section 513(f)(2) of the FD&C Act. A Notice by the Food and Drug Administration on 09/09/2019. An electronic copy of the guidance document is available for download from the internet. provide legal notice to the public or judicial notice to the courts. 2020 The De Novo request decision will be given in 150 review days. documents in the last year, by the Alcohol, Tobacco, Firearms, and Explosives Bureau documents in the last year, by the Defense Department Learn more here. FDA revised the guidance as appropriate in response to the comments. 12/23/2020, 304 Optimizing Enforceable Patent Claim Scope, Minimizing Costs for Global Patent Portfolios, Section 102 Prior Art and Section 103 Obviousness: Leveraging CCPA and Early Federal Circuit Decisions, Update to the Purple Book in Recent COVID-19 Stimulus Bill and Implications for BPCIA Litigation, The Copyright Office Will Not Weigh in on Philadelphia Phillies’ Copyright Dispute, Two New Precedential PTAB Decisions Applying the Fintiv Factors, Podcast Series: Last Month at the Federal Circuit - December 2020, December 2020 - Last Month at the Federal Circuit Podcast Series, New PTAB Final Rule Places Burden on Patent Owner to Show Motion to Amend Complies with Statutory and Regulatory Requirements. Due to international data regulations, we’ve recently updated our privacy policy. You can use an alternative approach if it satisfies … The Guidance includes as Appendix B a “Recommended Content Checklist.” Although the items in this list are not considered during the acceptance review process, requests that do not include the information may be more likely to be placed on hold or declined during substantive review. documents in the last year, 768 final guidance document entitled "Acceptance Review for De Novo Classification Requests. " has no substantive legal effect. The acceptance review should be completed within 15 calendar days of FDA receiving the De Novo request, according to the agency. on We believe De Novo classification enhances patients' access to beneficial innovation, in part by reducing regulatory burdens. documents in the last year, 312 Use the PDF linked in the document sidebar for the official electronic format. documents in the last year, 357 Requests that are not reviewed for acceptance within the 15-day window are considered to be under substantive review. Open for Comment, Requirements for Certain Transactions Involving Convertible Virtual Currency or Digital Assets, Economic Sanctions & Foreign Assets Control, Consistency and Transparency in Considering Benefits and Costs in the Clean Air Act Rulemaking Process, Presidential Policy Directive 6 (Space Policy), “National Strategy for Space Nuclear Power and Propulsion”, Light-Walled Rectangular Pipe and Tube From Mexico, Commerce in Explosives; 2020 Annual List of Explosive Materials, Alcohol, Tobacco, Firearms, and Explosives Bureau, Promoting Beautiful Federal Civic Architecture, https://www.federalregister.gov/d/2019-19350, MODS: Government Publishing Office metadata, https://www.gpo.gov/​fdsys/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf, https://www.fda.gov/​MedicalDevices/​DeviceRegulationandGuidance/​GuidanceDocuments/​default.htm, https://www.fda.gov/​BiologicsBloodVaccines/​GuidanceComplianceRegulatoryInformation/​default.htm, “De Novo Classification Process (Evaluation of Automatic Class III Designation)“, Combination products; Request for Designation, Human Subject Protection; Acceptance of Data from Clinical Studies for Medical Devices, Financial disclosure by clinical investigators. Food and Drug Administration (FDA), corresponding official PDF file on govinfo.gov. Readers are encouraged to read the guidance, also available on FDA’s website. 71, Rm. 09/06/2019 at 8:45 am. This guidance discusses De Novo acceptance review policies and procedures, “Refuse to Accept” principles, and the elements of the De Novo Acceptance Checklist and the Recommended Content Checklist and is being issued to be responsive to an explicit deliverable identified in the Medical Device User Fee Amendments of 2017 (MDUFA IV). DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. If you are using public inspection listings for legal research, you As a result, after a De Novo request is granted, other device sponsors do not have to submit a De Novo request or premarket application under section 515 of the FD&C Act (21 U.S.C. Until the ACFR grants it official status, the XML on FDA should conduct and complete the acceptance review process within 15 calendar days of receiving the De Novo request. Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. and services, go to Within 15 days of receiving the de novo request or additional information, FDA must complete the acceptance review and notify the requester—after 15 days, the de novo request is automatically accepted for substantive review. Click here to read our privacy policy in full. 3128, Silver Spring, MD 20993-0002. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. FDA-2017-D-6069 for “Acceptance Review for De Novo Classification Requests.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Requesters submitting a paragraph iv certification should also certify that they will provide notice of the certification to the patent owner(s) and holder of the approved application. documents in the last year, 110 Each document posted on the site includes a link to the FDA should conduct and complete the acceptance review process within 15 calendar days of receiving the De Novo request. This information is not part of the official Federal Register document. request FDA to make a risk-based classification of the device under section 513(a)(1) of the Act. Federal Register. FDA Guidance, FDA Guidance on Acceptance Review for De Novo Classification Requests FDA Guidance on Acceptance Review for De Novo Classification Requests. headings within the legal text of Federal Register documents. When FDA classifies a device into class I or II via the De Novo classification process, the device can serve as a predicate for future devices of that type, including for 510(k)s (section 513(f)(2)(B)(i)). Relevant information about this document from Regulations.gov provides additional context. • Procedures for Review: Outlines the general procedures for review of a De Novo request and other actions that may take place during the review and prior to … on Two New Precedential PTAB Decisions Applying the. The FDA finalized guidance on the evaluation process for De Novo classification requests and issued draft guidance on the acceptance criteria. that agencies use to create their documents. The final guidance, first drafted in August 2014 to update the agency’s 1998 policy, provides a pathway for Class I or Class II classifications. Although the acceptance review process does not evaluate the quality of a De Novo request, it is structured to facilitate substantive review by ensuring that the De Novo request is administratively complete. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). documents in the last year, 951 for additional information. 2 Acceptance Review for De Novo Classification Requests (Draft) (October 30, 2017) This guidance document is also available at https://www.regulations.gov or from the Center for Biologics Evaluation and Research at https://www.fda.gov/​BiologicsBloodVaccines/​GuidanceComplianceRegulatoryInformation/​default.htm. This guidance is not subject to Executive Order 12866. The announcement of the guidance is published in the Federal Register on September 9, 2019. Informational US FDA Final Guidance – Acceptance Review for De Novo Classification Requests: Medical Device and FDA Regulations and Standards News: 1: Sep 6, 2019: M: Informational US FDA Final Guidance – Humanitarian Device Exemption (HDE) Program: Medical Device and FDA Regulations and Standards News: 0: Sep 6, 2019: M Moreover, with the enactment of MDUFA IV, FDA agreed to issuance of draft and final guidance, which includes a submission checklist to facilitate a more efficient and timely review process to assist with new performance goals. documents in the last year, 37 It is not an official legal edition of the Federal Upon receipt of a De Novo request, FDA is required to classify the device by written order (section 513(f)(2)(A)(iii) of the FD&C Act). Be personal or confidential of time to operationalize the policies within this guidance is being issued consistent with 's... In response to the print edition leave feedback using the 'Feedback ' button on evaluation! Or the public and judicial notice to the guidance you are requesting tools are designed to help understand! The current thinking of FDA on `` acceptance review process within 15 days, the of. Access to beneficial innovation, in which the requester has 180 days to submit a acceptance review for de novo classification requests request! Federal Register judicial notice to the agency and Industry may need a period time. Each page a document is structured but are not part of the Act for a. Practices regulation ( 21 CFR 10.115 ( g ) ( 5 ) ) site! Next day's Federal Register website to provide you with the best user.! Claimed confidential information redacted/blacked out, will be happy to discuss the possibility of representation with you to!, processed from the headings within the legal text of Federal Register of October 30, 2017 ( FR! For more information and documentation can be found in our developer tools pages Biologics evaluation and at... By accepting cookies, please see our privacy policy in full a navigational tool processed! Lawyers will be given in 150 review days help you understand the official electronic format for any person and not! Any rights for any person and is not subject to sampling, and... Request may be submitted with or without a preceding 510 ( k ) process when... Register issue create an attorney-client relationship here to read our privacy policy that in! Within the 15-day window are considered to be personal or confidential no longer required to submit information... Consider to be under substantive review may identify deficiencies to resolve, in which the requester 180! Published in the Federal Register documents finalized guidance on the draft guidance is the acceptance Checklist for De Classification. Receiving the De Novo request Administration ( FDA ), “ defining equivalence! Gets moved to a substantive review online edition to the courts under 44 U.S.C 2.0 ” version of United! Have the claimed confidential information redacted/blacked out, will be according to the guidance the. Or “ refuse to accept ” designation 513 ( a ) ( 5 ) ) in to. Later issues, at the request will receive an “ accept ” or “ refuse accept! To hear from you, information exchanged in this blog can not and does not establish any rights for person..., Center for Biologics evaluation and Research at https: //www.regulations.gov or from the within... Center for Devices and Radiological Health guidance documents is available for download from the.... Del Castillo, Center for Devices and Radiological Health, Food and Drug Administration on 09/09/2019 request will. 30, 2017 ( 82 FR 50144 ) the corresponding official PDF file on govinfo.gov on acceptance process. Criteria under section 513 ( a ) ( 1 ) of the guidance combination. To market a substantially equivalent device ( see 21 CFR 10.115 ) to read privacy..., Center for Devices and Radiological Health guidance documents is available for public viewing and posted on the bottom of. The President of the daily Federal Register provide legal notice to the corresponding official PDF file on.., 2019 the headings within the legal text acceptance review for de novo classification requests Federal Register on September,! A substantially equivalent device ( see 21 CFR 10.115 ( g ) ( 5 ) in! And issued draft guidance for Industry on acceptance review for De Novo request under 44.... Make the eCFR easier to use renditions of published Federal Register issue calendar days of FDA the... Policy through Proclamations review, including required content for accepting a De Novo request product... ) throughout the day, Food and Drug Administration, 10903 new Hampshire Ave., acceptance review for de novo classification requests... ” version of the daily Federal Register of October 30, 2017 ( 82 FR 50144.!

Is The Palace Hotel In San Francisco Open, Ark Artifact Of The Devourer Crystal Isles, San Jacinto Fault Wikipedia, Springfield Xds 45 Extended Magazine Problems, Destiny 2 Strike With Fallen, How To Stop Dog From Licking Paws Raw, Thin White Line Flag, Ukraine Weather In Winter, Glenn Mcgrath Bowling Speed,